VERA on Nasdaq
Vera Therapeutics, Inc.
American pharmaceutical preparations company, incorporated in Delaware.
Price unavailable
Last updated Oct 18, 2026.
Overview
-$299.6MNet income, fiscal 20252
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Research and development | $215.3M | $126.2M | $78.2M |
| General and administrative | $100.2M | $41.0M | $23.8M |
| Total operating expenses | $315.5M | $167.2M | $102.0M |
| Loss from operations | -$315.5M | -$167.2M | -$102.0M |
| Interest income | $24.5M | $20.7M | $8.0M |
| Interest expense | -$7.5M | -$7.6M | -$3.8M |
| Other (expense) income, net | -$1.1M | $1.9M | $1.8M |
| Total other income, net | $15.9M | $15.0M | $6.0M |
| Loss before provision for income taxes | -$299.6M | -$152.1M | -$96.0M |
| Provision for income taxes | -$1.0K | -$1.0K | -$1.0K |
| Net loss | -$299.6M | -$152.1M | -$96.0M |
| Change in fair value on marketable securities | $393.0K | $142.0K | $251.0K |
| Comprehensive loss | -$299.2M | -$152.0M | -$95.7M |
| Net loss per share attributable to common stockholders, basic | -$4.66 | -$2.75 | -$2.25 |
| Net loss per share attributable to common stockholders, diluted | -$4.66 | -$2.75 | -$2.25 |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic | 64.2M shares | 55.3M shares | 42.7M shares |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted | 64.2M shares | 55.3M shares | 42.7M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $354.7M | $92.6M | ||
| Marketable securities | $359.9M | $548.2M | ||
| Prepaid expenses and other assets, current | $14.3M | $10.4M | ||
| Total current assets | $728.9M | $651.2M | ||
| Property and equipment, net | $1.4M | $960.0K | ||
| Operating lease right-of-use assets | $1.9M | $3.4M | ||
| Prepaid expenses and other assets, noncurrent | $2.6M | $131.0K | ||
| Total assets | $734.7M | $655.7M | ||
| Accounts payable | $21.9M | $7.7M | ||
| Operating lease liabilities | $549.0K | $1.5M | ||
| Accrued expenses and other liabilities, current | $31.0M | $16.2M | ||
| Total current liabilities | $53.5M | $25.4M | ||
| Long-term debt | $74.8M | $50.7M | ||
| Operating lease liabilities, noncurrent | $1.9M | $2.5M | ||
| Total liabilities | $130.2M | $78.5M | ||
| Class A common stock, $0.001 par value; 500,000,000 shares authorized as of December 31, 2025 and 2024; 71,267,429 and 63,559,858 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $71.0K | $64.0K | ||
| Additional paid-in capital | $1.4B | $1.0B | ||
| Accumulated other comprehensive income | $786.0K | $393.0K | ||
| Accumulated deficit | -$760.9M | -$461.2M | ||
| Total stockholders' equity | $604.5M | $577.2M | $101.7M | $76.9M |
| Total liabilities and stockholders' equity | $734.7M | $655.7M | ||
| Preferred stock par or stated value per share | $0.00 | $0.00 | ||
| Preferred stock shares authorized | 10.0M shares | 10.0M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $354.7M | $92.6M | ||
| Marketable securities | $359.9M | $548.2M | ||
| Prepaid expenses and other assets, current | $14.3M | $10.4M | ||
| Total current assets | $728.9M | $651.2M | ||
| Property and equipment, net | $1.4M | $960.0K | ||
| Operating lease right-of-use assets | $1.9M | $3.4M | ||
| Prepaid expenses and other assets, noncurrent | $2.6M | $131.0K | ||
| Total assets | $734.7M | $655.7M | ||
| Accounts payable | $21.9M | $7.7M | ||
| Operating lease liabilities | $549.0K | $1.5M | ||
| Accrued expenses and other liabilities, current | $31.0M | $16.2M | ||
| Total current liabilities | $53.5M | $25.4M | ||
| Long-term debt | $74.8M | $50.7M | ||
| Operating lease liabilities, noncurrent | $1.9M | $2.5M | ||
| Total liabilities | $130.2M | $78.5M | ||
| Class A common stock, $0.001 par value; 500,000,000 shares authorized as of December 31, 2025 and 2024; 71,267,429 and 63,559,858 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $71.0K | $64.0K | ||
| Additional paid-in capital | $1.4B | $1.0B | ||
| Accumulated other comprehensive income | $786.0K | $393.0K | ||
| Accumulated deficit | -$760.9M | -$461.2M | ||
| Total stockholders' equity | $604.5M | $577.2M | $101.7M | $76.9M |
| Total liabilities and stockholders' equity | $734.7M | $655.7M | ||
| Preferred stock par or stated value per share | $0.00 | $0.00 | ||
| Preferred stock shares authorized | 10.0M shares | 10.0M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net Income (Loss) | -$299.6M | -$152.1M | -$96.0M |
| Depreciation and amortization | $468.0K | $105.0K | $21.0K |
| Accretion of discount and amortization of premium on purchase of debt securities | -$7.0M | -$9.0M | -$4.4M |
| Accretion of loan exit fee and amortization of loan costs, net | $1.9M | $810.0K | $326.0K |
| Reduction in the carrying amount of operating lease right-of-use assets | $1.4M | $2.1M | $2.2M |
| Stock-based compensation | $37.9M | $20.8M | $11.5M |
| Payment of VT-109 license fee | $800.0K | $0 | $0 |
| Prepaid expense and other current assets | -$3.9M | $981.0K | $173.0K |
| Other assets | $51.0K | $351.0K | -$262.0K |
| Accounts payable | $13.9M | -$3.5M | -$873.0K |
| Accrued and other liabilities | $14.4M | $7.2M | -$2.2M |
| Operating lease liabilities | -$1.5M | -$2.4M | -$2.6M |
| Net cash used in operating activities | -$241.1M | -$134.7M | -$92.2M |
| Payment of VT-109 license fee | -$800.0K | $0 | $0 |
| Purchase of property and equipment | -$630.0K | -$972.0K | -$63.0K |
| Purchase of marketable securities | -$310.4M | -$703.0M | -$224.9M |
| Proceeds from maturities of marketable securities | $506.2M | $275.0M | $176.0M |
| Proceeds from sale of marketable securities | $0 | $4.0M | $9.5M |
| Net cash provided by (used in) investing activities | $194.3M | -$425.0M | -$39.4M |
| Proceeds from exercise of stock options and employee stock purchase plan | $7.0M | $13.4M | $1.1M |
| Proceeds from refinancing under loan and security agreement, net | $23.3M | $0 | $0 |
| Payment of deferred issuance costs related to unfunded loan commitments | -$3.5M | $0 | |
| Proceeds from short swing settlement | $500.0K | $37.0K | $0 |
| Proceeds from borrowings, net of costs | $0 | $0 | $24.7M |
| Repurchase of common stock | $0 | -$13.0K | $0 |
| Proceeds from issuance of common stock in follow-on offerings | $300.0M | $632.5M | $115.0M |
| Payment of issuance costs and underwriting fees related to follow-on offerings | -$18.4M | -$39.3M | -$7.3M |
| Net cash provided by financing activities | $308.9M | $606.7M | $133.5M |
| Net increase in cash and cash equivalents | $262.1M | $47.0M | $1.9M |
| Cash paid for interest expense | $6.7M | $6.7M | $3.4M |
| Purchases of property and equipment included in accounts payable | $252.0K | $0 | $0 |
| Follow-on offering costs included in accounts payable | $71.0K | $0 | $0 |
| Follow-on offering costs included in accrued and other liabilities | $343.0K | $0 | $0 |
No quarter-by-quarter statement was filed.
Leadership
Who has led Vera Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
2025
- Chief executive officerMarshall Fordyce May 13, 2021 to now10
- PresidentMarshall Fordyce May 13, 2021 to now10
- Chief financial officerJonathan Wolter May 13, 2021 to May 13, 202111
- Chief financial officerSean Grant Jul 15, 2021 to now12
Board members and other officers (21)
- Chief Commercial OfficerLaurence Matthew Skelton Jan 30, 2026 to now13
- Chief Regulatory OfficerNancy Lee Boman Aug 5, 2026 to now14
- Chief Medical OfficerRobert Brenner Jan 8, 2024 to now15
- Chief Development OfficerWilliam D. Turner Jan 9, 2024 to now16
- Chief Medical OfficerCelia Lin May 13, 2021 to Aug 23, 202317
- Chief Development OfficerJoanne Curley May 13, 2021 to Aug 23, 202318
- SVP, Finance, Chief Acct OffcrJoseph R. Young May 13, 2021 to now19
- Board memberChristopher Hite Mar 9, 2026 to now20
- Board memberJames R. Meyers Nov 26, 2025 to now21
- Board memberChristy J. Oliger Jun 11, 2024 to now22
- Board memberMichael M. Morrissey May 25, 2022 to now23
- Board memberAndrew Cheng May 13, 2021 to now24
- Board memberBeth C. Seidenberg May 13, 2021 to now25
- Board memberKurt Von Emster May 13, 2021 to May 18, 202126
- Board memberMaha Katabi May 13, 2021 to now27
- Board memberMarshall Fordyce May 13, 2021 to now10
- Board memberPatrick G. Enright May 13, 2021 to now28
- Board memberScott W. Morrison May 13, 2021 to now29
- Board memberKimball Hall Dec 13, 2021 to now30
- General counselJane Wright Mitchell Mar 25, 2026 to now31
- General counselJason S. Carter Nov 20, 2024 to now32
Timeline
- May 13, 2021New chief executive Marshall Fordyce becomes CEO10
Filings
407 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 59 major events, 195 insider forms, 55 large holders, 78 other. The latest 20:
- Sep 17, 20264 EDGAR
- Sep 15, 20268-K EDGAR
- Sep 14, 20264 EDGAR
- Sep 4, 20264 EDGAR
- Sep 2, 2026144 EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 12, 20264/A EDGAR
- Aug 12, 20264/A EDGAR
- Aug 12, 20264/A EDGAR
- Aug 10, 202610-Q EDGAR
- Aug 10, 20268-K EDGAR
- Aug 7, 2026SCHEDULE 13G EDGAR
- Aug 5, 20264 EDGAR
- Aug 5, 20263 EDGAR
- Jul 30, 2026SCHEDULE 13G/A EDGAR
- Jul 9, 20264 EDGAR
- Jul 9, 20268-K EDGAR
- Jul 7, 20268-K EDGAR
- Jun 24, 20264 EDGAR
- Jun 23, 2026144 EDGAR
The 407 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 55 such filings since October 2021, the latest 10:
- Aug 14, 2026SCHEDULE 13G/A
- Aug 7, 2026SCHEDULE 13G
- Jul 30, 2026SCHEDULE 13G/A
- May 15, 2026SCHEDULE 13G/A
- Apr 1, 2026SCHEDULE 13G
- Mar 27, 2026SCHEDULE 13G/A
- Mar 11, 2026SCHEDULE 13G
- Mar 5, 2026SCHEDULE 13D/A
- Feb 17, 2026SCHEDULE 13G/A
- Feb 5, 2026SCHEDULE 13G/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 5,747,760 | $246.6M | 0.0% | +659,658 |
| Avoro Capital Advisors LLC | 5,723,888 | $245.6M | 2.2% | −165,000 |
| State Street Corp | 4,148,786 | $178.0M | 0.0% | +785,148 |
| Deep Track Capital, LP | 4,000,000 | $171.6M | 2.5% | −106,067 |
| Deerfield Management Company, L.P. | 3,916,400 | $168.1M | 2.1% | +194,300 |
| Kynam Capital Management, LP | 2,890,059 | $124.0M | 6.9% | −508,165 |
| Morgan Stanley | 2,799,459 | $120.1M | 0.0% | +2,430,699 |
| Sofinnova Investments, Inc. | 2,793,987 | $119.9M | 6.4% | No change |
| Fmr LLC | 2,774,070 | $119.0M | 0.0% | +97,648 |
| Vanguard Capital Management LLC | 2,755,413 | $118.2M | 0.0% | +71,806 |
| Eversept Partners, LP | 2,212,770 | $94.9M | 5.2% | +39,484 |
| Logos Global Management LP | 2,200,000 | $94.4M | 4.1% | New |
| Integral Health Asset Management, LLC | 1,750,000 | $75.1M | 3.1% | +150,000 |
| Bellevue Group AG | 1,710,808 | $73.4M | 1.5% | +37 |
| Geode Capital Management, LLC | 1,692,442 | $72.6M | 0.0% | +122,365 |
| Alliancebernstein L.P. | 1,591,043 | $64.0M | 0.0% | +276,801 |
| Goldman Sachs Group Inc | 1,380,835 | $59.3M | 0.0% | +246,866 |
| Frontier Capital Management Co LLC | 1,295,405 | $55.6M | 0.5% | +743,912 |
| Pictet Asset Management Holding SA | 1,249,414 | $53.6M | 0.1% | +197,831 |
| Deutsche Bank Ag\ | 1,102,106 | $47.3M | 0.0% | +569,640 |
| Qube Research & Technologies Ltd | 1,083,179 | $46.5M | 0.1% | +541,380 |
| Woodline Partners LP | 1,001,037 | $43.0M | 0.1% | No change |
| American Century Companies Inc | 866,243 | $37.2M | 0.0% | +137,913 |
| Vanguard Portfolio Management LLC | 642,873 | $27.6M | 0.0% | +89,902 |
| Voya Investment Management LLC | 642,562 | $27.6M | 0.0% | +352,086 |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12SEC EDGARSean Grant, Chief financial officer
- 13
- 14
- 15
- 16
- 17SEC EDGARCelia Lin, Chief Medical Officer
- 18
- 19
- 20SEC EDGARChristopher Hite, Board member
- 21SEC EDGARJames R. Meyers, Board member
- 22SEC EDGARChristy J. Oliger, Board member
- 23SEC EDGARMichael M. Morrissey, Board member
- 24SEC EDGARAndrew Cheng, Board member
- 25SEC EDGARBeth C. Seidenberg, Board member
- 26SEC EDGARKurt Von Emster, Board member
- 27SEC EDGARMaha Katabi, Board member
- 28SEC EDGARPatrick G. Enright, Board member
- 29SEC EDGARScott W. Morrison, Board member
- 30SEC EDGARKimball Hall, Board member
- 31
- 32SEC EDGARJason S. Carter, General counsel